Johns Hopkins Medicine researchers developed a nasal DNA vaccine against tuberculosis, the world's leading infectious disease killer. The innovative approach targets drug-resistant bacterial strains by fusing two TB genes to strengthen immune respons
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Johns Hopkins Team Develops Therapeutic, Nasally-Delivered DNA Vaccine for Tuberculosis

Tuberculosis Disease targeted
Nasal Vaccine Delivery method
DNA-Based Gene Fusion Approach
Drug-Tolerant Bacteria Target mechanism
Drug-Tolerant TB Bacteria target
Gene Fusion approach
World'S Leading Infectious Disease Killer significance
Nasal delivery method